Experience

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $175 million SEC-registered common stock and pre-funded warrants…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a SEC-registered follow-on offering of 4,573,863 shares of common stock…

Davis Polk advised the representatives of several initial purchasers in connection with a Rule 144A offering by DexCom, Inc. of $1.05 billion aggregate principal amount of its 0.250%…

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by NanoString Technologies, Inc. of $230 million aggregate principal amount of its 2.625% convertible…

Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Atara Biotherapeutics, Inc. of its common stock for up to an aggregate amount of $100 million. Based in…

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Revance Therapeutics, Inc. of $287.5 million aggregate principal amount of its 1.75% convertible senior…

Davis Polk advised the joint lead book-running managers and representatives of the several underwriters in connection with a $110.5 million SEC-registered common stock offering by…

Davis Polk advised the underwriters in connection with the $150 million initial public offering of 10,000,000 American Depositary Shares of BioNTech SE. In addition, the underwriters have…

Davis Polk advised the underwriters in connection with the $97.75 million initial public offering of 6,516,667 shares of common stock of Aprea Therapeutics, Inc., which includes 850,000…

Davis Polk advised the underwriter in connection with the SEC-registered offering by PTC Therapeutics, Inc. of 2,475,248 shares of its common stock and the initial purchaser in a concurrent…